Putting the award page together from the records…
Putting the award page together from the records…
Novartis Pharmaceuticals Corporation received this contract from 261-Network Contract Office 21 (36C261), Department of Veterans Affairs: $3.99M obligated so far for drugs and biologicals. Its period of performance ended 2026-09-30.
Key facts · data as of Oct 23, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.
Cite this page: SpendQuery, Award 36C26126F0007, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_36C26126F0007_3600_36F79720D0180_3600
Novartis Pharmaceuticals Corporation: all federal awards · Department of Veterans Affairs: spending · 261-Network Contract Office 21 (36C261): what it buys · The follow-on: recompete brief
PLUVICTO DRUG
Up for re-bid: ends 2026-09-30. Recompete brief → · 6505--Rubidium (Rb-82) Generators, 612-C79072, Base: 10/01/26 - 09/30/27 Base plus 1 Option Year ↗
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
1 action since 2025-10-01. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2025-10-01 | 0 | $3.99M | PLUVICTO DRUG |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗